In Brief: Third Dose of mRNA-based COVID-19 Vaccines for Immunocompromised Persons

Date: September 20, 2021 Issue #:  1633Summary:  The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech(Comirnaty) and Moderna(Spikevax) to include administration of a third dose in persons ≥12 years old (Pfizer/BioNTech) or ≥18 years old (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent (see Table 1).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research